Dare Bioscience Inc (DARE) USD0.0001
Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing products for women’s health. Its portfolio of differentiated therapies expands treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Its product pipeline includes three product candidates in advanced stages of clinical development, three in Phase I clinical development and three in pre-clinical stage development. The product candidates in its pipeline include DARE-BV1, Ovaprene, Sildenafil Cream, 3.6%, DARE-HRT1, DARE-FRT1, DARE-VVA1, DARE-LARC1, ORB-204 and ORB-214, and DARE-RH1. DARE-BV1 is focused on the treatment for bacterial vaginosis. Ovaprene is designed to provide multiple weeks of contraceptive protection and Sildenafil Cream, 3.6% is for the treatment of female sexual arousal disorders are under advanced stages of clinical development.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.